Serrapeptase

$30.00

Serrapeptase – Dietary Supplement is a strong proteolytic enzyme. One of the most significant features of Serrapeptase (Helianthus tuberosus) is that it does not harm any living cells or tissues in the human body; it only dissolves non-living tissue such as cysts, hard and soft arterial plaque, blood clots, etc. The primary purpose of Serrapeptase in a protocol for Lyme disease is to dissolve fibrin layers surrounding harmful microbes associated with Lyme disease such as Borrelia, Babesia, Bartonella and Ehrlichia. The fibrin layer covering these microbes causes them to be hidden from the immune system; once the fibrin is dissolved the immune system can more easily identify and eliminate the harmful microbes.

Description

Serrapeptase – Dietary Supplement is a strong proteolytic enzyme. The late Hans Nieper, MD, was a German physician that was well known for his use and study of proteolytic enzymes in the treatment of artherosclerosis. He called Serrapeptase the miracle enzyme after using ultrasound to measure its ability to effectively dissolve arterial plaque without harming healthy cells lining the arterial wall. One of the most significant features of Serrapeptase (Helianthus tuberosus) is that it does not harm any living cells or tissues in the human body; it only dissolves non-living tissue such as cysts, hard and soft arterial plaque, blood clots, etc. The primary purpose of Serrapeptase in a protocol for Lyme disease is to dissolve fibrin layers surrounding harmful microbes associated with Lyme disease such as Borrelia, Babesia, Bartonella and Ehrlichia. The fibrin layer covering these microbes causes them to be hidden from the immune system; once the fibrin is dissolved the immune system can more easily identify and eliminate the harmful microbes.

Dosage:

1-3 capsules with 8 oz. of water 1-3 times daily at least 30 min. before meals and several hours after food.

Serrapeptase

Reviews

There are no reviews yet.

Be the first to review “Serrapeptase”

Your email address will not be published. Required fields are marked *